Adge Pharmaceuticals partners with Cyan Bio of Korea to advance treatments for rare pediatric diseases in Asian countries

MOUNTAIN VIEW, Calif., April 25, 2022 /PRNewswire/ — Adge Pharmaceuticals (“Adge”) has entered into a licensing agreement with Korea-based Cyan Bio, Inc. (“Cyan”). Cyan will receive exclusive rights to commercialize elocalcitol in key territories in Asia for the treatment of Rett syndrome and osteogenesis imperfecta. Territories include Korea, Greater China, Japan, India and Southeast Asian countries. Along with the license agreement, Cyan will take an equity stake in Adge.

As previously announced (https://adgepharm.com/news/mar-22-2022/), Adge has been granted a worldwide license to RO269228, a clinical-stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analogue that has demonstrated its efficacy and safety in several phase 2 clinical trials. Moreover, its mechanism of action is highly relevant to treat the pathogenesis of several rare diseases, including Rett syndrome and osteogenesis imperfecta, which Adge targets as priority indications.

dr. Kalev KaskCEO and Founder of Adge, said, “Partnering with Cyan is an important step towards expanding Adge’s international reach as it continues to develop its key asset, elocalcitol, for the treatment of Rett disease and osteogenesis imperfecta, two rare pediatric diseases. for which Asian countries are an increasingly important market. We are extremely happy to have been able to partner with Cyan as a specialist in these markets”.

Michelle KimCEO of Cyan, added, “We are delighted to partner with Adge to develop elocalcitol to address a significant unmet need for patients in Asia.”

Rett syndrome is a neurodevelopmental disorder caused by a mutation in MECP2 gene and almost exclusively affects girls. It is characterized by normal early growth and development followed by slowed development, slowed brain and head growth, loss of deliberate use of hands, distinctive hand movements , gait problems, seizures, autistic behavior and intellectual disability. Rett syndrome is the second most common neurodevelopmental disorder in girls after Down syndrome, affecting approximately 1 in 9,000 to 10,000 women.

Osteogenesis imperfecta, also known as brittle bone disease, is a group of genetic conditions that primarily affect the bones. People with this disease have bones that fracture easily, often as a result of mild trauma or without apparent cause. Multiple fractures are common and, in severe cases, can occur even before birth. Osteogenesis imperfecta affects approximately 1 in 10,000 to 20,000 people worldwide.

Adge Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan indications.

“Bio cyan (www.cyanbio.com) is a Korea-based company focused on identifying and developing promising opportunities that address unmet medical needs.

SOURCEAdge Pharmaceuticals Inc.

Comments are closed.